Elesclomol (STA-4783)

For research use only.

Catalog No.S1052

10 publications

Elesclomol (STA-4783) Chemical Structure

Molecular Weight(MW): 400.5

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.

Size Price Stock Quantity  
10mM (1mL in DMSO) EUR 186 In stock
EUR 167 In stock
EUR 314 In stock
EUR 953 In stock
EUR 1739 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Elesclomol (STA-4783) has been cited by 10 publications

4 Customer Reviews

  • BMC Genomics 2014 15(1), 263. Elesclomol (STA-4783) purchased from Selleck.

    Treatment with elesclomol inhibits cancer cell growth and induces apoptosis by increasing ROS levels. a. Cell growth of SMOV2, IGROV1, and OVCA432 ovarian cancer cells treated with elesclomol in the presence or absence of the antioxidant NAC for 72 h. Cell growth was measured using the WST-1 assay and quantified relative to DMSO treated controls.

    Oncotarget, 2016, 7(35):56933-56943. Elesclomol (STA-4783) purchased from Selleck.

  • Overexpression of GILZ favors oxidative cell death Dose-response of ROS production (HE staining) (A) or cell death (PI staining) (B) in indicated cells exposed toincreasing concentrations of elesclomol for 24 h (mean ± SD, n = 3, *p < 0.05). Alternatively, cells were treated with elesclomol for 24 h with or without pre-incubation with10 mM N-Acetyl Cysteine (NAC) for 12 h before HE staining (A) or PI staining (B) (mean ± SD, n = 3, *p < 0.05).

    Int J Biochem Cell Biol, 2017, 85:166-174. Elesclomol (STA-4783) purchased from Selleck.

    The proliferation of PC3 and LNCaP cells exposed to elesclomol at a range of concentrations for 48 h was assessed using MTT assay. Results are expressed as percentage of MTT absorbance of untreated cells at 0 h. p < .05 and p < .01 compared to untreated controls. Data are means ± SEM; n = 4.

    Int J Radiat Biol, 2017, 93(2):194-203. Elesclomol (STA-4783) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (HSP90) Inhibitors

Biological Activity

Description Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
Targets
HSP70 [1]
(Cell-free assay)
In vitro

Elesclomol significantly induces the expression of heat shock stress response genes and metallothionein genes, a signature transcription profile indicative of oxidative stress in Hs294T cells. Elesclomol (100 nM) rapidly induces Hsp70 RNA levels with a 4.8-fold increase at 1 hour and a 160-fold increase at 6 hours in Ramos Burkitt's lymphoma B cells in consistent with the intracellular ROS content which increases by 20% as early as 0.5 hour and 385% at 6 hours, and the induction of Hsp70 can be blocked by antioxidants N-acetylcysteine (NAC) and Tiron pretreatment. Elesclomol increases the number of early and late apoptotic cells with 3.7- and 11-fold through the induction of oxidative stress, which can be completely blocked by NAC, while having little effect on normal cells. [1] Elesclomol significantly inhibits the cell viability of SK-MEL-5, MCF-7, and HL-60 with IC50 of 110 nM, 24 nM and 9 nM, respectively. [2] Elesclomol induces copper-dependent ROS generation and cytoxicity in yeast. Instead of working through a specific cellular protein target, Elesclomol interacts with the electron transport chain (ETC), a biologically coherent set of processes occurring in the mitochondrion, to generate high levels of ROS within the organelle and consequently cell death. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NOS-1 cell MnLmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2XVR2lvcGmkaYTpc44hd2ZiaIXtZY4hVk:VLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhOy54NnWtNFUh|ryP MXzTRW5ITVJ?
CAL-51 cell M4TYWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NULsUI1DUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytOVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF{NjDuUS=> NI[zdXlUSU6JRWK=
ABC-1 cell MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1W2V2lvcGmkaYTpc44hd2ZiaIXtZY4hSUKFLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlM3PSCwTR?= MkTyV2FPT0WU
A2780 cell MmW4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{\UfWlvcGmkaYTpc44hd2ZiaIXtZY4hSTJ5OECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlU6PCCwTR?= M1XvPXNCVkeHUh?=
ES1 cell MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M36xZmlvcGmkaYTpc44hd2ZiaIXtZY4hTVNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD63OFkhdk1? NVLsbWxSW0GQR1XS
HUTU-80 cell MlX5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmLrTY5pcWKrdHnvckBw\iCqdX3hckBJXVSXLUiwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44QTFibl2= MlXNV2FPT0WU
NCI-H292 cell NE\GS2tIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NH;1SYdKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlkzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC56OE[gcm0> MULTRW5ITVJ?
NB69 cell MoTRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEDsVXdKdmirYnn0bY9vKG:oIHj1cYFvKE6ENkmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlIzKG6P MYDTRW5ITVJ?
ES8 cell MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEf3R|lKdmirYnn0bY9vKG:oIHj1cYFvKEWVODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuN|Ihdk1? NYTCfW1IW0GQR1XS
BCPAP cell NYDIfHdiT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWjJT2FDUW6qaXLpeIlwdiCxZjDoeY1idiCEQ2DBVEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOzRibl2= NUfmPJZUW0GQR1XS
T-24 cell M3;qZ2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2HxRmlvcGmkaYTpc44hd2ZiaIXtZY4hXC1{NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOVUhdk1? NIj3dnJUSU6JRWK=
EW-16 cell M2\pVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYfJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTF4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT62NUBvVQ>? M4HlWXNCVkeHUh?=
OVCAR-5 cell NXHaW5A2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnvTTY5pcWKrdHnvckBw\iCqdX3hckBQXkODUj21JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU45OyCwTR?= MmToV2FPT0WU
SF126 cell M2LHd2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkLDTY5pcWKrdHnvckBw\iCqdX3hckBUTjF{NjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuPVUhdk1? NEDYVoFUSU6JRWK=
KP-4 cell NXr1RXlOT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWfxbVViUW6qaXLpeIlwdiCxZjDoeY1idiCNUD20JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4yPyCwTR?= NF;4THBUSU6JRWK=
GAMG cell MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4C1XGlvcGmkaYTpc44hd2ZiaIXtZY4hT0GPRzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuOVEhdk1? NVqzNmdJW0GQR1XS
HOS cell MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFXx[ZlKdmirYnn0bY9vKG:oIHj1cYFvKEiRUzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuOVMhdk1? M1nRc3NCVkeHUh?=
CHL-1 cell NWP6UlRST3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mn3jTY5pcWKrdHnvckBw\iCqdX3hckBEUExvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuPFEhdk1? MmLnV2FPT0WU
AGS cell NInWTYRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Ml2zTY5pcWKrdHnvckBw\iCqdX3hckBCT1NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{Lki2JI5O MlWyV2FPT0WU
MDA-MB-157 cell MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnX2TY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtNVU4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi57MjDuUS=> MmrMV2FPT0WU
HSC-3 cell NVjBTII2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYKyOGx2UW6qaXLpeIlwdiCxZjDoeY1idiCKU1OtN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvODJibl2= NEewNWlUSU6JRWK=
CAL-72 cell NGPl[GdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{LYcWlvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUeyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4xOiCwTR?= MnSzV2FPT0WU
NBsusSR cell NUjHR2V6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXntZYxzUW6qaXLpeIlwdiCxZjDoeY1idiCQQoP1d3NTKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy5zMzDuUS=> MkXSV2FPT0WU
ES7 cell M2XnNmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3;6bmlvcGmkaYTpc44hd2ZiaIXtZY4hTVN5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz61PUBvVQ>? NVLOPHVDW0GQR1XS
H-EMC-SS cell M1zQTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYnJcohq[mm2aX;uJI9nKGi3bXHuJGguTU2FLWPTJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{43QCCwTR?= MoXmV2FPT0WU
NCI-H1703 cell MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn60TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG3NFMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjZ6IH7N NHLJVVVUSU6JRWK=
BHT-101 cell MlXVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M37rVGlvcGmkaYTpc44hd2ZiaIXtZY4hSkiWLUGwNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvPzJibl2= M17jW3NCVkeHUh?=
SK-OV-3 cell Mk\hS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXrT[GdkUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3PWk0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy55NTDuUS=> M1LXVnNCVkeHUh?=
EW-24 cell MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mm\vTY5pcWKrdHnvckBw\iCqdX3hckBGXy1{NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuPFMhdk1? NYjDXXlEW0GQR1XS
PSN1 cell M3jmbmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2HDTWlvcGmkaYTpc44hd2ZiaIXtZY4hWFOQMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuPFQhdk1? Mnm3V2FPT0WU
OVCAR-8 cell MlXtS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWTOT2w6UW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk05KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy57OTDuUS=> M1jZOXNCVkeHUh?=
NCI-H1563 cell NVfBTVQ{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUnJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUW2N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvOTNibl2= M3rXV3NCVkeHUh?=
SW756 cell MnLtS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWHJcohq[mm2aX;uJI9nKGi3bXHuJHNYPzV4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND6xN{BvVQ>? NWPXcHFrW0GQR1XS
A375 cell M3XiNmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmX4TY5pcWKrdHnvckBw\iCqdX3hckBCOzd3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND6xOEBvVQ>? NF33OldUSU6JRWK=
Ca9-22 cell M{Xtc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFPkcoFKdmirYnn0bY9vKG:oIHj1cYFvKEOjOT2yNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvOjVibl2= NInkOnZUSU6JRWK=
SW1990 cell NFXDU4JIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYjWeG1[UW6qaXLpeIlwdiCxZjDoeY1idiCVV{G5PVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjN{IH7N NEG5bGZUSU6JRWK=
ES4 cell MnLPS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEn1[VRKdmirYnn0bY9vKG:oIHj1cYFvKEWVNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuN|khdk1? MW\TRW5ITVJ?
HCE-T cell MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnK3TY5pcWKrdHnvckBw\iCqdX3hckBJS0VvVDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuOFUhdk1? NH\DNFFUSU6JRWK=
MOLT-16 cell NXL4WHBnT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlHNTY5pcWKrdHnvckBw\iCqdX3hckBOV0yWLUG2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE42OyCwTR?= NITkeIxUSU6JRWK=
HSC-4 cell M4LRNmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Ml\FTY5pcWKrdHnvckBw\iCqdX3hckBJW0NvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuPEBvVQ>? M3nJSHNCVkeHUh?=
NCI-SNU-1 cell MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1qxZ2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLWPOWU0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC56NjDuUS=> M4POTHNCVkeHUh?=
EW-11 cell Mn;nS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NF7zXpFKdmirYnn0bY9vKG:oIHj1cYFvKEWZLUGxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE46KG6P Mm\HV2FPT0WU
HT-1080 cell M3e3WWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXPJcohq[mm2aX;uJI9nKGi3bXHuJGhVNTFyOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlk6KG6P M37NZ3NCVkeHUh?=
MES-SA/Dx5 cells MlPjR5l1d3SxeHnjbZR6KGG|c3H5 NX7XRmRIS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUWVLWPBM2R5PSClZXzsd{whUUN3ME21JI5O NInVXVUzOzl|N{m4NS=>
SW1710 cell MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXTJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTdzMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuNVYhdk1? M1\uenNCVkeHUh?=
EW-1 cell NXuzRW5JT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{ixeGlvcGmkaYTpc44hd2ZiaIXtZY4hTVdvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuNlQhdk1? MWnTRW5ITVJ?
BV-173 cell NILOdplIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYHNboEyUW6qaXLpeIlwdiCxZjDoeY1idiCEVj2xO|Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjN7IH7N M4DQWnNCVkeHUh?=
TE-8 cell NIjtPJBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXXJcohq[mm2aX;uJI9nKGi3bXHuJHRGNThiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkSxJI5O NYTyVIl3W0GQR1XS
G-401 cell MmHtS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVvJcohq[mm2aX;uJI9nKGi3bXHuJGcuPDBzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT60N{BvVQ>? M2DkVHNCVkeHUh?=
KOSC-2 cell M2XHeWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWOzeppSUW6qaXLpeIlwdiCxZjDoeY1idiCNT2PDMVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjR3IH7N NUnaWoxWW0GQR1XS
HuCCT1 cell NVLab3hDT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGh2S0OWMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuOVIhdk1? NF2ySGhUSU6JRWK=
FADU cell NIrsOGlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUPjU4JEUW6qaXLpeIlwdiCxZjDoeY1idiCIQVTVJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU43PiCwTR?= NVftRnRVW0GQR1XS
MHH-ES-1 cell MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnzuTY5pcWKrdHnvckBw\iCqdX3hckBOUEhvRWOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPjlibl2= NEPLWHlUSU6JRWK=
ES3 cell NH;YWGVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1TEcGlvcGmkaYTpc44hd2ZiaIXtZY4hTVN|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT63PUBvVQ>? NYm3b2wzW0GQR1XS
OVCAR-4 cell MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUTDcmpvUW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk01KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS56NzDuUS=> NFfxTIZUSU6JRWK=
HD-MY-Z cell Ml7US5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NX3IdG5KUW6qaXLpeIlwdiCxZjDoeY1idiCKRD3NXU1bKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS57MTDuUS=> NETJdnpUSU6JRWK=
human JAR cell MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFLwZnpKdmirYnn0bY9vKG:oIHj1cYFvKEqDUjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuPVchdk1? NVHxVIFSW0GQR1XS
A427 cell MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn2xTY5pcWKrdHnvckBw\iCqdX3hckBCPDJ5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nj6wO{BvVQ>? M{S1ZXNCVkeHUh?=
697 cell M1\NbWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3rzfmlvcGmkaYTpc44hd2ZiaIXtZY4hPjl5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nj6xN{BvVQ>? NXHzTmhvW0GQR1XS
OVCAR-3 cell NFHCOpZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVzJcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GULUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlIhdk1? MmXaV2FPT0WU
human NB14 cell NXfwZXB2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHLufo1KdmirYnn0bY9vKG:oIHj1cYFvKE6EMUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlY1KG6P NIC3XJRUSU6JRWK=
GB-1 cell MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkS1TY5pcWKrdHnvckBw\iCqdX3hckBISi1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nj63NUBvVQ>? NUThVGZEW0GQR1XS
COR-L105 cell NYPOXXdST3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Moe2TY5pcWKrdHnvckBw\iCqdX3hckBEV1JvTEGwOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvPzZibl2= MkfDV2FPT0WU
647-V cell NUnGO5ZVT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYDEZWJnUW6qaXLpeIlwdiCxZjDoeY1idiB4NEetWkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvQSCwTR?= MoXWV2FPT0WU
human K5 cell M1rIRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXfzXpNxUW6qaXLpeIlwdiCxZjDoeY1idiCNNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUegcm0> NGrEfGJUSU6JRWK=
DMS-273 cell NYjzRXZCT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVrJcohq[mm2aX;uJI9nKGi3bXHuJGROWy1{N{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlA3KG6P NYfYWlRDW0GQR1XS
UM-UC-3 cell MkDjS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXnyb3ZSUW6qaXLpeIlwdiCxZjDoeY1idiCXTT3VR{0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py5yNjDuUS=> NUDtXHo3W0GQR1XS
HEL cell NIHRdG1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXvJcohq[mm2aX;uJI9nKGi3bXHuJGhGVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdwMEigcm0> MUXTRW5ITVJ?
human KU-19-19 cell MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVLJcohq[mm2aX;uJI9nKGi3bXHuJGtWNTF7LUG5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4xQSCwTR?= MXrTRW5ITVJ?
MC-IXC cell M1\YW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXTJcohq[mm2aX;uJI9nKGi3bXHuJG1ENUm[QzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuNVchdk1? MVrTRW5ITVJ?
human H4 cell M{n1[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWj2UXhJUW6qaXLpeIlwdiCxZjDoeY1idiCKNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuNlUhdk1? MnfRV2FPT0WU
NUGC-3 cell MknWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Ml76TY5pcWKrdHnvckBw\iCqdX3hckBPXUeFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlM{KG6P NF\POoNUSU6JRWK=
CHP-212 cell NX7PR3hbT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYjJcohq[mm2aX;uJI9nKGi3bXHuJGNJWC1{MUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlM1KG6P NYDBPFU5W0GQR1XS
human SW982 cell NEKw[FFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NE\lVFVKdmirYnn0bY9vKG:oIHj1cYFvKFOZOUiyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{41PCCwTR?= MoPxV2FPT0WU
C-33-A cell MoLYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXK2VWlkUW6qaXLpeIlwdiCxZjDoeY1idiCFLUOzMWEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjV6IH7N M2WwbXNCVkeHUh?=
PC-3 cell M4HXc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mn20TY5pcWKrdHnvckBw\iCqdX3hckBRSy1|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nz64PUBvVQ>? M17lVnNCVkeHUh?=
COLO-684 cell M1O4N2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXT5V|BrUW6qaXLpeIlwdiCxZjDoeY1idiCFT1zPMVY5PCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTlwMkGgcm0> M1rEbXNCVkeHUh?=
SNU-387 cell M1v6[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEPr[FlKdmirYnn0bY9vKG:oIHj1cYFvKFOQVT2zPFch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF06NjR7IH7N NWPVOXJ{W0GQR1XS
U251 cell NUn4bIpsT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlzrTY5pcWKrdHnvckBw\iCqdX3hckBWOjVzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;OT64OkBvVQ>? M3\nfXNCVkeHUh?=
A673 cell NUj4d|NET3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NF76bldKdmirYnn0bY9vKG:oIHj1cYFvKEF4N{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNU43KG6P MWHTRW5ITVJ?
human T47D cell MnfFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NV7WWVNqUW6qaXLpeIlwdiCxZjDoeY1idiCWNEfEJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVYvPzlibl2= NX3yV4E6W0GQR1XS
A549 cell NV\OSFRjT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1jWSGlvcGmkaYTpc44hd2ZiaIXtZY4hSTV2OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG5MlYhdk1? NIDDXmxUSU6JRWK=
PC-14 cell NEfoeWxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEGzWI1KdmirYnn0bY9vKG:oIHj1cYFvKFCFLUG0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlQvPzNibl2= MonPV2FPT0WU
A704 cell M1Xlemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHjI[ItKdmirYnn0bY9vKG:oIHj1cYFvKEF5MESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yO{41PSCwTR?= NF;zSWJUSU6JRWK=
MCF7 cell MorBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MoTkTY5pcWKrdHnvckBw\iCqdX3hckBOS0Z5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;M{GuN|Yhdk1? MnvFV2FPT0WU
PC3 cells NWLrepE4TnWwY4Tpc44h[XO|YYm= MkLWTY5pcWKrdHnvckBw\iCSRFuxMY1m\GmjdHXkJGFMXCCyaH;zdIhwenmuYYTpc44h[XRiVHjyN|A5KHKnc3nkeYUhcW5iaIXtZY4hWEN|IHPlcIx{KGK7IFXMTXNCNCCLQ{WwQVAvOTF|IN88US=> MlTMNlE{PDF4N{W=
F-36P cells MWnQdo9tcW[ncnH0bY9vKGG|c3H5 NHXjeo9CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF[tN|ZRKGOnbHzzMEBKSzVyPUCuNlgh|ryP NF\yXlEzOTN2MU[3OS=>
OCI-AML2 cells MWLQdo9tcW[ncnH0bY9vKGG|c3H5 MXnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE:FST3BUWwzKGOnbHzzMEBKSzVyPUCuN|Uh|ryP Mmm4NlE{PDF4N{W=
K562 cells MUHQdo9tcW[ncnH0bY9vKGG|c3H5 M1\RdWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS{W2NkBk\WyuczygTWM2OD1zODFOwG0> NI\3bYUzOTN2MU[3OS=>

... Click to View More Cell Line Experimental Data

In vivo Although Elesclomol (25-100 mg/kg) as a single agent shows no antitumor activity in nude mouse xenograft models of human breast cancers (MDA435, MCF7 and ZR-75-1), lung cancer (RER) or lymphoma (U937), Elesclomol substantially enhances the efficacy of chemotherapeutic agents such as paclitaxel in these models, both in terms of tumor regression and extended survival of mice. [4]

Protocol

Cell Research:[1]
- Collapse
  • Cell lines: Hs294T, HSB2, and Ramos
  • Concentrations: Dissolved in DMSO at a concentration of 10 mM, final concentrations ~500 nM
  • Incubation Time: 18, or 24 hours
  • Method: Cells are treated with various concentrations of Elesclomol for 18 or 24 hours. The level of intracellular ROS is monitored using the DCFDA probe, which emits a green fluorescence on oxidation. Cell death is determined by flow cytometry of cells double stained with Annexin V/FITC and propidium iodide (PI) using a Vybrant Apoptosis assay kit.
    (Only for Reference)
Animal Research:[4]
- Collapse
  • Animal Models: Female CD-1 nude mice bearing established MDA435 breast cancer xenograft tumors
  • Dosages: ~100 mg/kg
  • Administration: Intravenous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 80 mg/mL (199.75 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40%PEG300+5%Tween80 +50%H2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 400.5
Formula

C19H20N4O2S2

CAS No. 488832-69-5
Storage powder
in solvent
Synonyms N/A
Smiles CN(C(=S)C1=CC=CC=C1)NC(=O)CC(=O)NN(C)C(=S)C2=CC=CC=C2

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How can we use the compound for in vivo mouse studies?

  • Answer:

    S1052 in 1% DMSO+30% polyethylene glycol+1% Tween 80 is a suspension, it is fine for oral administration. You can also dissolve S1052 in 0.5-1% CMC-Na solution and treat the mice by oral gavage.

HSP (HSP90) Signaling Pathway Map

Related HSP (HSP90) Products

Tags: buy Elesclomol (STA-4783) | Elesclomol (STA-4783) supplier | purchase Elesclomol (STA-4783) | Elesclomol (STA-4783) cost | Elesclomol (STA-4783) manufacturer | order Elesclomol (STA-4783) | Elesclomol (STA-4783) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID